Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131 I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma.
Clin Nucl Med
; 48(5): 426-427, 2023 May 01.
Article
em En
| MEDLINE
| ID: mdl-36728291
ABSTRACT
ABSTRACT An 84-year-old man with history of metastatic pheochromocytoma/paraganglioma (mPPGL) received surgery 13 years ago, with recent biopsy-proven mPPGL in the T11. 123 I-MIBG scan showed MIBG-avid liver and osseous. Given his medical condition and body habitus (weight, 45 kg; height, 140 cm), the patient was treated with high-specific-activity 131 I-MIBG (Azedra) 300 mCi ×2. He tolerated the medication and was totally asymptomatic. Series 123 I-MIBG scan showed good responses till 22 months after the first treatment at the last visit. This is probably the oldest and smallest adult mPPGL patient treated with Azedra and with prolonged good response.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Paraganglioma
/
Neoplasias do Sistema Nervoso Periférico
/
Feocromocitoma
/
Neoplasias Encefálicas
/
Segunda Neoplasia Primária
/
Neoplasias das Glândulas Suprarrenais
Limite:
Adult
/
Aged80
/
Humans
/
Male
Idioma:
En
Revista:
Clin Nucl Med
Ano de publicação:
2023
Tipo de documento:
Article